Robust recovery in non-COVID-19 business ensures a beat in Q1
04/05/21 -"Benefiting from strong demand for sample technology solutions and the QuantiFERON-TB test, Qiagen’s non-COVID-19 business was back in the black in Q1 21. Expectedly, COVID-19 products witnessed a ..."
Pages
62
Language
English
Published on
04/05/21
You may also be interested by these reports :
03/06/26
Despite a reduction in our target price, as discussed in the EPS section, our positive recommendation on Qiagen remains unchanged. This optimism is ...
29/05/26
Elekta’s Q4 results revealed an adjusted EBIT exceeding expectations, although sales fell short. The company offered qualitative guidance for ...
26/05/26
Piling up assets is no strategy
25/05/26
The modest TP reduction reflects downward revisions to DCF and NAV, driven by lower near-term earnings (as discussed in the ‘EPS’ section). While our ...